Quality of Evidence:
Coadministration may increase erythromycin concentrations. Careful monitoring of therapeutic and adverse effects is recommended.
Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of erythromycin. Careful monitoring of therapeutic and adverse effects is recommended when erythromycin is used concomitantly administered with ritonavir. Norvir Summary of Product Characteristics, AbbVie Ltd, September 2016.
View all available interactions with
Ritonavir (RTV) by clicking